| 朱晓峰,蔡晓燕.伊马替尼治疗慢性髓细胞白血病慢性期临床疗效观察[J].安徽医药,2015,19(10):1993-1996. |
| 伊马替尼治疗慢性髓细胞白血病慢性期临床疗效观察 |
| Clinical efficacy of imatinib on chronic myeloid leukemia in chronic phase |
| 投稿时间：2015-03-20 |
| DOI： |
| 中文关键词: 慢性髓细胞白血病 慢性期 伊马替尼 疗效 |
| 英文关键词: chronic myeloid leukemia chronic phase imatinib efficacy |
| 基金项目: |
|
| 摘要点击次数: 3371 |
| 全文下载次数: 154 |
| 中文摘要: |
| 目的 分析甲磺酸伊马替尼(IM)治疗慢性髓系白血病(CML)慢性期的临床疗效及影响疗效的因素。 方法 随访观察74例CML慢性期患者,IM中位治疗剂量为400(200～600)mg·d-1,评估其临床疗效,总生存时间和疾病无进展生存时间,并对相关疗效影响因素进行分析。 结果 中位随访时间为20(6～72)个月,累积达到血液学缓解(CHR)为98.6%,血液学中位缓解时间1(1～3)月；63例(85.1％)达到主要细胞遗传学缓解(MCyR),中位达MCyR时间为9(5～24)个月；53例(71.6％)达完全细胞遗传学缓解(CCyR),41例(55.4％)达到主要分子生物学缓解(MMR)；6例(8.1％)达到完全分子生物学缓解(CMR)；初治组及复治组应用IM治疗后CHR及MCyR差异无统计学意义,但CCyR及MMR差异均有统计学意义(P＜0.016)；由EUTOS评分区分的低危组与高危组应用IM治疗后CHR差异无统计学意义,但MCyR、CCyR及MMR差异均有统计学意义(P＜0.020)；其中初治组与复治组及EUTOS评分低危组与高危组OS差异无统计学意义,但其PFS差异均有统计学意义(P分别为0.021和0.004)。 结论 IM用于CML慢性期患者治疗可获得极高的血液学缓解率和较高细胞遗传学缓解率,不良反应少,提高了患者生存质量,延长患者的生存时间；在CML确诊早期应用可提高疗效,IM治疗前时间大于6个月或EUTOS评分高危组可影响IM疗效。 |
| 英文摘要: |
| Objective To explore the clinical efficacy and influence factors of imatinib mesylate(IM)treatment of chronic myeloid leukemia(CML)in chronic phase. Methods We followed up 74 cases of patients with chronic phase CML,IM median dose being 400(200 ~ 600)mg·d-1,to assess its clinical efficacy,overall survival and progression-free survival,and to analyze the related factors affecting the efficacy. Results Median follow-up was 20(6~72)months.Cumulative complete hematological remission(CHR)rate was 98.6%.The median time for hematological remission was 1(1~3)months.63 cases(85.1%)reached MCyR,the median time being 9(5~24)months;53 cases(71.6%),41 cases(55.4%)and 6 cases(8.1%)reached CCyR,MMR and CMR,respectively.There were no significant differences in CHR and MCyR after treatment with IM in the initial treatment and retreatment group,but differences in CCyR and MMR were statistically significant(P<0.016).There was no significant difference in CHR after treatment with IM in low-risk group and high risk group distinguished by EUTOS score,but differences in MCyR,CCyR and MMR were statistically significant(P<0.020).There is no significant difference in OS between the groups,but difference in PFS was statistically significant(P=0.021,P=0.004). Conclusion With IM treatment for chronic phase CML,higher hematological remission rates and higher rates of cytogenetic response were achieved.There were also fewer adverse reactions,improved quality of life and prolonged survival time of patients.Immediate use of IM after the diagnosis of CML could improve the outcome of the treatment.The efficacy might be affected if IM was used more than 6 months after the diagnosis or in high risk group defined by EUTOS score. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
